<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043090</url>
  </required_header>
  <id_info>
    <org_study_id>D5086C00001</org_study_id>
    <secondary_id>2021-000336-55</secondary_id>
    <nct_id>NCT05043090</nct_id>
  </id_info>
  <brief_title>Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC</brief_title>
  <acronym>SAMETA</acronym>
  <official_title>A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib&#xD;
      in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or&#xD;
      metastatic PRCC (Papillary Renal Cell Carcinoma)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, randomised, open label, 3 arm, multi-centre, international study&#xD;
      assessing the efficacy and safety of savolitinib plus durvalumab compared with sunitinib in&#xD;
      participants with MET-driven (without co-occurring FH mutations), unresectable and locally&#xD;
      advanced or metastatic PRCC, who have not received any prior systemic anti-cancer therapy in&#xD;
      the metastatic setting. The study will also investigate the contribution of durvalumab to the&#xD;
      savolitinib plus durvalumab combination.&#xD;
&#xD;
      Approximately 200 participants will be randomised in a 2:1:1 ratio to one of the following&#xD;
      intervention groups: savolitinib (600mg, oral, once daily) plus durvalumab (1500mg IV Q4W),&#xD;
      sunitinib (50mg, oral, once daily for 4 consecutive weeks, followed by a sunitinib-free&#xD;
      interval of 2-weeks, Q6W), or durvalumab monotherapy (1500mg IV Q4W).&#xD;
&#xD;
      Participants will continue to receive study intervention until objective radiological PD per&#xD;
      RECIST 1.1 is assessed by the investigator, unacceptable toxicity occurs, consent is&#xD;
      withdrawn or another discontinuation criterion is met.&#xD;
&#xD;
      Depending on the preferred subsequent therapy, participants randomised to the durvalumab&#xD;
      monotherapy arm will be eligible to switch to receive savolitinib in combination with&#xD;
      durvalumab at the time of objective radiological PD assessed by BICR per RECIST 1.1, without&#xD;
      any intervening systemic anti-cancer therapy following discontinuation of durvalumab&#xD;
      monotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 8, 2021</start_date>
  <completion_date type="Anticipated">May 20, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 8, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) /savolitinib plus durvalumab relative to sunitinib</measure>
    <time_frame>Approximately 28 months post first subject randomized</time_frame>
    <description>Defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause.&#xD;
The analysis will include all randomised participants as randomised, regardless of whether the participant withdraws from therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) /savolitinib plus durvalumab relative to sunitinib</measure>
    <time_frame>Approximately 28 months and approximately 42 months post first subject randomized</time_frame>
    <description>Defined as time from randomisation until the date of death due to any cause. The comparison will include all randomised participants as randomised regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) / savolitinib plus durvalumab relative to sunitinib</measure>
    <time_frame>Approximately 28 months post first subject randomized</time_frame>
    <description>Defined as the proportion of participants who have a Complete Response (CR) or Partial Response (PR) as determined by BICR per RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) / savolitinib plus durvalumab relative to sunitinib</measure>
    <time_frame>Approximately 28 months post first subject randomized</time_frame>
    <description>Defined as the time from the date of first documented response until date of documented progression per RECIST 1.1 as assessed by BICR or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) at 24 and 48 weeks /savolitinib plus durvalumab relative to sunitinib</measure>
    <time_frame>Approximately 28 months post first subject randomized</time_frame>
    <description>Defined as the percentage of participants who have a CR or PR or who have Stable Disease (SD) per RECIST 1.1 as assessed by BICR for at least 23 or 47 weeks, respectively after randomisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomisation to second progression or death (PFS2) /savolitinib plus durvalumab relative to sunitinib</measure>
    <time_frame>Approximately 28 months and 42 months post first subject randomized</time_frame>
    <description>Defined as time from randomisation to the earliest of the progression event (following the initial progression), subsequent to the first subsequent therapy or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of patient-reported symptoms, functioning, and HRQoL /savolitinib plus durvalumab relative to sunitinib</measure>
    <time_frame>Approximately 28 months post first subject randomized</time_frame>
    <description>Time to deterioration and change from baseline in symptoms, functioning, and HRQoL as measured by FKSI-19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) / savolitinib plus durvalumab relative to durvalumab monotherapy</measure>
    <time_frame>Approximately 28 months post first subject randomized</time_frame>
    <description>Defined as the proportion of participants who have a Complete Response (CR) or Partial Response (PR) as determined by BICR per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) / savolitinib plus durvalumab relative to durvalumab monotherapy</measure>
    <time_frame>Approximately 28 months post first subject randomized</time_frame>
    <description>Defined as the time from the date of first documented response until date of documented progression per RECIST 1.1 as assessed by BICR or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) /savolitinib plus durvalumab relative to durvalumab monotherapy</measure>
    <time_frame>Approximately 28 months post first subject randomized</time_frame>
    <description>Defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause.&#xD;
The analysis will include all randomised participants as randomised, regardless of whether the participant withdraws from therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the PK of savolitinib pre-dose</measure>
    <time_frame>Approximately 28 months post first subject randomized</time_frame>
    <description>Plasma concentration of savolitinib and its metabolites pre-dose (Ctrough / trough plasma concentration : measured concentration at the end of a dosing interval at steady state [taken directly before next administration]) in participants randomised to savolitinib plus durvalumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the PK of savolitinib post-dose</measure>
    <time_frame>Approximately 28 months post first subject randomized</time_frame>
    <description>Plasma concentration of savolitinib and its metabolites post-dose (C1h and C3h) in participants randomised to savolitinib plus durvalumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the PK of durvalumab pre-dose</measure>
    <time_frame>Approximately 28 months post first subject randomized</time_frame>
    <description>Serum concentration of durvalumab pre-dose (Ctrough / trough plasma concentration : measured concentration at the end of a dosing interval at steady state [taken directly before next administration]) in participants randomised to savolitinib plus durvalumab or durvalumab monotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the PK of durvalumab / Cmax (maximum plasma concentration)</measure>
    <time_frame>Approximately 28 months post first subject randomized</time_frame>
    <description>Serum concentration of durvalumab at the end of infusion (Cmax) in participants randomised to savolitinib plus durvalumab or durvalumab monotherapy.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Papillary Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>savolitinib 600mg plus durvalumab 1500mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sunitinib 50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>durvalumab 1500mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>savolitinib</intervention_name>
    <description>Tablets : 3 × 200 mg tablets once daily</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>AZD6094, HMPL-504, volitinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>durvalumab</intervention_name>
    <description>Concentrate for solution for IV infusion : 1500 mg durvalumab every 4 weeks</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib</intervention_name>
    <description>Capsules : 2 x 25mg capsules once daily 4 weeks on, 2 weeks off</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Sutent, SU11248</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed unresectable and locally advanced or metastatic PRCC&#xD;
&#xD;
          -  PRCC must be centrally confirmed as MET-driven using a sponsor-designated central&#xD;
             laboratory validated NGS assay&#xD;
&#xD;
          -  No prior systemic anti-cancer treatment in the metastatic setting; no prior exposure&#xD;
             to MET inhibitors, Durvalumab or Sunitinib in any setting&#xD;
&#xD;
          -  Karnofsky Score &gt;70&#xD;
&#xD;
          -  At least one lesion, not previously irradiated, that can be accurately measured at&#xD;
             baseline&#xD;
&#xD;
          -  Adequate organ and bone marrow function&#xD;
&#xD;
          -  Life expectancy ≥12weeks at Day 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of serious liver disease, with or without, normal LFTs, such as cirrhosis or&#xD;
             Wilson's disease&#xD;
&#xD;
          -  Spinal cord compression or brain metastases, unless asymptomatic and stable on&#xD;
             treatment for at least 14 days prior to study intervention&#xD;
&#xD;
          -  Active or prior cardiac disease (within past 6 months) or clinically significant ECG&#xD;
             abnormalities and/or factors/medications that may affect QT and/or QTc intervals&#xD;
&#xD;
          -  Active infection including HIV, TB, HBV and HCV&#xD;
&#xD;
          -  Active or prior documented autoimmune or inflammatory disorders&#xD;
&#xD;
          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of study&#xD;
             intervention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toni Choueiri</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>T4000IAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 5</city>
        <zip>15000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 8</city>
        <zip>180 81</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>México</city>
        <zip>06100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Queretaro</city>
        <zip>76090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>?08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally</keyword>
  <keyword>Advanced</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Savolitinib</keyword>
  <keyword>Sunitinib</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>MET Driven</keyword>
  <keyword>Papillary Renal Cell Carcinoma</keyword>
  <keyword>Renal Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.&#xD;
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

